Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated…
Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber: the first application of APT to launch a new standard in wound care
Introducing Antimicrobial Polymer Technology (APT™) in POLTX_Fiber™, a Class IIb advanced wound…
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
February 22, 2026 16:00 ET | Source: Dyne Therapeutics, Inc. - Late-breaking…
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position…
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private…
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
February 20, 2026 09:05 ET | Source: Ernexa Therapeutics Inc. Live video…
Candel Therapeutics Announces Proposed $100 Million Public Offering
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel…
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled…
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million…
